09.04 2023

Antibodies for T-Cell Activation (T-cube Bispecific Antibody Platform) has received a U.S. patent.

Antibodies For T-Cell Activation' has been granted a U.S. invention patent, Certificate No. 11,725,058.

07.31 2023

IBI302 is advancing to Phase III clinical trial by Innovent Biologics

The global development rights for IBI302 have been licensed to Innovent Biologics INC (1801.HK).

07.14 2023

Listed on the Emerging Stock Board at the Taipei Exchange, stock code 6945

01.14 2023

Phase I clinical trial application for bispecific antibody AP505 submitted to U.S. FDA.

Announcement of the submission of a Phase I human clinical trial application for the bispecific Antibody Program AP505 to the U.S. Food and Drug Administration (FDA)

01.10 2023

Approved an initial public offering (IPO) or stock launch